Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Strontium89 is an FDA-approved, non-opioid radiopharmaceutical indicated for the treatment of painful skeletal metastases caused by cancer and is agnostic of the primary tumor.
Lead Product(s): Strontium Chloride, Sr-89
Therapeutic Area: Oncology Product Name: Metastron
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Q BioMed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 10, 2021